Global Cord Blood Corporation(CORBF.US)

Company Encyclopedia
View More
name
Global Cord Blood Corporation
CORBF.US
Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018.
387.01 B
CORBF.USMarket value -Rank by Market Cap -/-

Financial Score

11/01/2026 Update
C
Health Care ServicesIndustry
Industry Ranking47/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE10.82%B
    • Profit Margin40.30%A
    • Gross Margin85.26%A
  • Growth ScoreB
    • Revenue YoY12.54%B
    • Net Profit YoY3.49%C
    • Total Assets YoY11.65%B
    • Net Assets YoY15.13%A
  • Cash ScoreC
    • Cash Flow Margin248.12%C
    • OCF YoY12.54%B
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreC
    • Gearing Ratio42.76%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Three Major Characteristics of Fund Winners in 2025

    In 2025, China's active equity fund market experienced a repricing of capabilities, with over 90% of products achieving positive returns and a median return close to 30%. The performance of the industry showed significant differentiation, with nonferrous metals rising by 94.73%, while food and beverages fell by 9.69%. The annual ranking of funds was influenced by track selection and rebalancing ability, emphasizing the value of active management and the importance of timing in track selection. Overall, 2025 marked a fundamental shift in the evaluation logic of funds, with a significant recovery in the overall profitability effect of active equity funds

    Wallstreetcn·
    HK
    20070
    +2.87%
    Wallstreetcn·
    HK
    20070
    +2.87%

    U.S. stock market midday update: Innventure plummets 13.47%, trading volume surges, sector trends trigger market fluctuations?

    Innventure fell 13.47%; Blackstone Group fell 5.20%, with a transaction volume of USD 749 million; BlackRock fell 2.94%, with a transaction volume of USD 432 million; KKR Group fell 2.16%, with a transaction volume of USD 250 million; Brookfield fell 2.70%, with a market value of USD 107.4 billion

    Tracking Unusual Activity·
    US
    INV
    +1.21%
    Tracking Unusual Activity·
    US
    INV
    +1.21%

    TheraVectys, a French biotechnology company, plans to go public in Hong Kong, which may break industry norms

    TheraVectys SA is considering an initial public offering (IPO) in Hong Kong, which could take place as early as this year. This move is relatively rare among biotech companies outside of China, as they typically choose to list in European and American markets. If successful, it will break the industry norm and reflect China's rise in the field of innovation and the attractiveness of the Hong Kong market. TheraVectys primarily develops lentiviral vectors, with investors including Tethys Invest SAS

    Stheadline·
    Stheadline·

    BLA for subcutaneous form of LEQEMBI accepted in China, could be first anti-amyloid treatment with at-home injection.

    Pending approval, lecanemab has the potential to be the initial and solitary anti-amyloid therapy in China providing at-home injections from the start of treatment for this advancing and persistent ailment. This development could lead to groundbreaking progress in the country's healthcare system for managing such conditions.

    Unusual Whales·
    Unusual Whales·

    Premier Li Qiang conducts research in Guangdong, listening to the report on the planning and development of the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone

    Premier Li Qiang conducted research in Guangdong, listening to reports on the planning and development of the Shenzhen-Hong Kong Technology Innovation Cooperation Zone, emphasizing that technological innovation is key to the future. Li Qiang pointed out the need to strengthen the leading role of enterprises in innovation, improve policy and financial support, rely on the Guangdong-Hong Kong-Macao Greater Bay Area to gather innovative resources, and promote R&D cooperation in emerging fields. He also inspected the low-altitude economy and the robotics industry, calling for the improvement of the industrial ecosystem, exploration of new business models, promotion of new technology applications, and support for economic development. Governments at all levels need to strengthen coordination, optimize the business environment, and stimulate endogenous economic momentum

    AASTOCKS·
    AASTOCKS·
    © 2026 Longbridge｜Disclaimer